Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1975 1
1980 2
1982 1
1986 2
1989 1
1990 2
1993 2
1994 1
1995 1
1996 4
1997 4
1998 4
1999 3
2000 4
2001 4
2002 6
2003 5
2004 12
2005 7
2006 6
2007 6
2008 4
2009 6
2010 3
2011 6
2012 13
2013 11
2014 8
2015 8
2016 15
2017 7
2018 13
2019 10
2020 13
2021 10
2022 15
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Male Breast Carcinoma In Situ"
Page 1
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3–07/TROG 07.01 trial investigators. Chua BH, et al. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. Lancet. 2022. PMID: 35934006 Clinical Trial.
BACKGROUND: Whole breast irradiation (WBI) after conservative surgery for ductal carcinoma in situ (DCIS) reduces local recurrence. We investigated whether a tumour bed boost after WBI improved outcomes, and examined radiation dose fractionation sensitivity f …
BACKGROUND: Whole breast irradiation (WBI) after conservative surgery for ductal carcinoma in situ (DCIS) reduces local …
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Valtorta E, et al. Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. Mod Pathol. 2015. PMID: 26449765 Free article. Clinical Trial.
We sought to develop criteria for ERBB2-positivity (HER2) in colorectal cancer to ensure accurate identification of ERBB2-amplified metastatic colorectal cancer patients suitable for enrollment in a phase II trial of ERBB2-targeted therapy (HERACLES trial). A two-st …
We sought to develop criteria for ERBB2-positivity (HER2) in colorectal cancer to ensure accurate identification of ERBB2-amplified metastat …
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. Tarantino P, et al. JAMA Oncol. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286. JAMA Oncol. 2022. PMID: 35737367 Free PMC article.
IMPORTANCE: It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 breast cancer. ...The study included 5235 patients with stage I through III, ERBB2-negative invasive breast cancer. Tumors were …
IMPORTANCE: It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 …
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM. Ross JS, et al. Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16. Cancer. 2018. PMID: 29338072 Free PMC article.
Other significant differences in mutation frequency were observed for genes in the PI3K/MTOR and mismatch repair pathways. CONCLUSIONS: Although observed less often than in breast or upper gastrointestinal carcinomas, indications for which anti-HER2 therapies are approved, …
Other significant differences in mutation frequency were observed for genes in the PI3K/MTOR and mismatch repair pathways. CONCLUSIONS: Alth …
Testosterone therapy and breast histopathological features in transgender individuals.
Baker GM, Guzman-Arocho YD, Bret-Mounet VC, Torous VF, Schnitt SJ, Tobias AM, Bartlett RA, Fein-Zachary VJ, Collins LC, Wulf GM, Heng YJ. Baker GM, et al. Mod Pathol. 2021 Jan;34(1):85-94. doi: 10.1038/s41379-020-00675-9. Epub 2020 Sep 16. Mod Pathol. 2021. PMID: 32939016 Free PMC article.

Columnar cell change and mild inflammation were also less likely to occur in subjects receiving TT (p < 0.05), but were not linked to the duration of TT. Atypia and ductal carcinoma in situ were detected in 11 subjects (2.5%) all of whom received TT ranging from

…

Columnar cell change and mild inflammation were also less likely to occur in subjects receiving TT (p < 0.05), but were not linked to the

…
MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis.
Gan J, Liu S, Zhang Y, He L, Bai L, Liao R, Zhao J, Guo M, Jiang W, Li J, Li Q, Mu G, Wu Y, Wang X, Zhang X, Zhou D, Lv H, Wang Z, Zhang Y, Qian C, Feng M, Chen H, Meng Q, Huang X. Gan J, et al. Exp Mol Med. 2022 Aug;54(8):1290-1305. doi: 10.1038/s12276-022-00837-6. Epub 2022 Aug 30. Exp Mol Med. 2022. PMID: 36042375 Free PMC article.
Here, we aimed to determine how miR-375 modulates CRPC progression and thereafter to evaluate the therapeutic potential of human umbilical cord mesenchymal stem cell (hucMSC)-derived exosomes loaded with miR-375 antisense oligonucleotides (e-375i). We used miRNA in situ hy …
Here, we aimed to determine how miR-375 modulates CRPC progression and thereafter to evaluate the therapeutic potential of human umbilical c …
Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features.
Hou R, Grimm LJ, Mazurowski MA, Marks JR, King LM, Maley CC, Lynch T, van Oirsouw M, Rogers K, Stone N, Wallis M, Teuwen J, Wesseling J, Hwang ES, Lo JY. Hou R, et al. Radiology. 2022 Apr;303(1):54-62. doi: 10.1148/radiol.210407. Epub 2022 Jan 4. Radiology. 2022. PMID: 34981975 Free PMC article.
Background Improving diagnosis of ductal carcinoma in situ (DCIS) before surgery is important in choosing optimal patient management strategies. ...Conclusion Machine learning models that use radiomic features applied to mammographic calcifications may help predict …
Background Improving diagnosis of ductal carcinoma in situ (DCIS) before surgery is important in choosing optimal patient mana …
Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.
Zeng J, Edelweiss M, Ross DS, Xu B, Moo TA, Brogi E, D'Alfonso TM. Zeng J, et al. Arch Pathol Lab Med. 2021 Jun 1;145(6):728-735. doi: 10.5858/arpa.2020-0293-OA. Arch Pathol Lab Med. 2021. PMID: 33112958 Free PMC article.
.-: It is unclear whether HER2+ tumors expressing both estrogen receptor (ER) and progesterone receptor (PR), that is, triple-positive breast carcinomas (TPBCs), show unique morphologic and clinical features and response to neoadjuvant chemotherapy (NAC). ...H-score …
.-: It is unclear whether HER2+ tumors expressing both estrogen receptor (ER) and progesterone receptor (PR), that is, triple-positive br …
Heterogeneity of ductal carcinoma in situ and its effects on management.
Mokbel K, Cutuli B. Mokbel K, et al. Lancet Oncol. 2006 Sep;7(9):756-65. doi: 10.1016/S1470-2045(06)70861-0. Lancet Oncol. 2006. PMID: 16945771 Review.
Data derived from histopathological analysis, natural history, radiological characteristics, molecular markers, and clinical outcome indicate that ductal carcinoma in situ (DCIS) is a heterogeneous disease, meaning that no one treatment strategy is best, but …
Data derived from histopathological analysis, natural history, radiological characteristics, molecular markers, and clinical outcome …
Gene-based vaccines and immunotherapeutics.
Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P. Liu M, et al. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14567-71. doi: 10.1073/pnas.0404845101. Epub 2004 Aug 27. Proc Natl Acad Sci U S A. 2004. PMID: 15333750 Free PMC article. Review.
We have focused our clinical efforts, at this time, on the use of recombinant viral vectors for both vaccine as well as cytokine gene transfer studies. We currently have four clinical programs in cancer immunotherapy. Two nonspecific immunotherapy programs are under …
We have focused our clinical efforts, at this time, on the use of recombinant viral vectors for both vaccine as well as cytokine gene …
199 results